2020 — Montréal, Canada • September 13 to 16
September 12—Board Meeting and DSP Exam
September 13—CE Courses
September 14–16—Scientific Sessions
2019 — Barcelona, Spain • September 23 to 26
Scientific topics covered: The Utility of Human Stem Cell Models of Nervous System Disorders - Progress and Clinical Proof of Concept, Emerging In Vitro Models and Their Application in Safety, Hot Topics in the Central Nervous System, Can Safety Pharmacology Studies Support the Assessment of Immune-Related Adverse Events?, Thoughts on Translation, Leveraging the In Silico World of Data to Identify Personalized Medicine Approaches for Novel Drug Targets, How Clinicians and Clinical Pharmacologists View Safety Pharmacology Data, Recent Trends in High Performance Computing for Safety Pharmacology, What Do Biomarkers Mark? A Safety Pharmacology Perspective, Impact of Early Safety Pharmacology Derisking Strategies and Techniques, Strategies for Getting to FIH and Beyond Efficiently and Safely, and Revisiting ICH S7A and S7B.
2018 — Washington, DC • September 29 to October 3
Scientific topics Covered: Science=Solutions for the US Opioid Crisis, The Promise and Perils of Heart Failure Gene Therapy, Secondary Pharmacology: From the Test Tube to the Clinic, Next Generation Non-Opiate Pain Management, Safety Pharmacology/FDA Discussion on the Gastrointestinal System, CiPA Real-Life Implementation, Cardio-Oncology, Central Nervous System and Sensory Assessments: Established and Emerging Nonclinical Drug Safety Testing Strategies, Advanced Imaging Techniques in Preclinical Safety, In Silico Approaches, From Bench to Bedside—Translational Clinical Pharmacology Designs, and Interactive Case Studies.
2017 — Berlin, Germany • September 23 to 27
Scientific topics Covered: Gender Differences in Cardiovascular Diseases, The Pathophysiology and Treatment of Tinnitus, Oncology Drug Safety Testing in the 21st Century, Updates on the Hot Topics within CNS, Current Topics in the Translation and Validation of Safety Pharmacology Studies, Best Practices for New Biological Entities and New Modalities, Disease Models and Personalized Medicine, In Vitro Microphysiological Systems to Predict Safety, In Silico Modeling for Cardiac Drug Safety, Animal Models and Species Selection, CiPA Challenges and Opportunities from Nonclinical, Clinical, and Regulatory Perspectives and Interactive Case Studies.
2016 — Vancouver, Canada • September 18 to 21
Scientific topics Covered: Safety Pharmacology Across the Globe, Translational Cardiovascular Safety Pharmacology, Receptor Pharmacology, Advances in Technologies: In Vitro and In Silico Models, Practical Pharmacology, Personalized Medicine, Translational CNS and Respiratory Safety Pharmacology, State-of-the-Art Technologies and Methods, Translational Biomarkers: Bridging the Gap, Paediatric & Fetal Clinical Pharmacology, Regulatory Session, as well as SPS Oral Communications (from posters) and CSPT Trainee Presentations (from posters).
2020 SPS NORTHEAST REGIONAL MEETING: REAL WORLD SAFETY PHARMACOLOGY AND ITS IMPACT ON HUMAN HEALTH
Save the Date for the Safety Pharmacology Society Northeast Regional Meeting, which will be held at Merck Research Laboratories in Boston, MA on May 19, 2020. Registration is free for Students and Postdocs; registration for SPS members is $50; Nonmembers fee is $75. Included with the registration fee are continental breakfast, coffee breaks/snacks, lunch, and an evening reception (serving Hors D’ Oeuvres & Alcohol).
Alan Bass (Co-chair), Alysia Anne Chaves (Co-chair), Susan Goody (Co-chair), Khuram Chaudhary, Donald Hodges, Emily Kaushik, Malar Pannirselvam, and Christopher Stock.
Hosted by: Merck Research Laboratories
Location: 33 Avenue Louis Pasteur, Boston, MA 02115
Date: May 19, 2020
Registration Time: 8:00 AM–8:45 AM ET
Meeting Time: 9:00 AM–5:00 PM ET
Networking Reception: 5:00 PM–6:30 PM ET
Past Regional Meetings
To view information from previous regional meetings, please click here.
Distinguished Service Award
The Safety Pharmacology Society Distinguished Service Award (DSA) is an honor given to an individual who has substantially contributed to the field of Safety Pharmacology in one or more of the following areas: specific research achievements, champions of the field, lifelong contribution to the field, substantial specific contribution, visionary direction, regulatory decisions, science and technology of the field, education, mentorship in the field, collaboration between industry, academia, and regulatory.
Previous Distinguished Service Award Recipients
Junior Investigator Award
Eligible candidates for the Junior Investigator Award include students (undergraduate or graduate), technical staff, and junior scientists, postdoctoral fellows (< 5 years), and early career lab heads. The candidate should have less than 10 years experience in the field of safety pharmacology. Candidates may come from within academia, contract research organizations, pharmaceutical or biotechnology industry, government or engaged in preclinical research in safety pharmacology.
Exclusion criteria include previous Junior Travel Award winners, professors (undergraduate or graduate programs) and management personnel (e.g. laboratory head, principal investigator, or supervisor/mentor).
Previous Junior Investigator Award Recipients